bioMerieux (OTCMKTS:BMXMF – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $87.42, but opened at $83.31. bioMerieux shares last traded at $83.31, with a volume of 10 shares traded.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft downgraded bioMerieux from a “buy” rating to a “hold” rating in a research note on Friday, April 24th. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.
View Our Latest Report on BMXMF
bioMerieux Stock Performance
bioMerieux Company Profile
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.
See Also
- Five stocks we like better than bioMerieux
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
